Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum CCFM1112
- Development stage
- Preclinical
- Lead developer
- Nanjing Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum CCFM1112 is a live biotherapeutic product, specifically a probiotic strain, being investigated for the treatment of chronic constipation. [1] In a randomized, double-blind, placebo-controlled clinical trial involving 56 volunteers with chronic constipation, a 4-week intervention with B. longum CCFM1112 resulted in significant improvements in stool consistency and quality of life scores related to constipation. [1, 2, 3] The mechanism of action involves modulating the gut microbiota, leading to an increased abundance of beneficial bacterial genera such as Blautia, Anaerobutyricum, and Streptococcus. [1, 2, 3] Additionally, it elevates the fecal levels of certain metabolites, including linoleic acid, gamma-aminobutyric acid (GABA), and arachidonic acid. [1, 2, 3] The strain was developed by researchers at Jiangnan University in China. [3]
- Other names
- 双歧杆菌CCFM1112
Beyond the preview
Go deeper on Bifidobacterium longum CCFM1112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum CCFM1112.